Eastwood Bio-Medical Canada Inc (EBM) - Total Liabilities
Based on the latest financial reports, Eastwood Bio-Medical Canada Inc (EBM) has total liabilities worth CA$1.73 Million CAD as of April 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Eastwood Bio-Medical Canada Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how Eastwood Bio-Medical Canada Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Eastwood Bio-Medical Canada Inc Competitors by Total Liabilities
The table below lists competitors of Eastwood Bio-Medical Canada Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AtlasClear Holdings, Inc.
NYSE MKT:ATCH
|
USA | $55.94 Million |
|
Mao Bao Inc
TW:1732
|
Taiwan | NT$168.72 Million |
|
Cranswick PLC
LSE:CWK
|
UK | GBX693.00 Million |
|
KESM Industries Bhd
KLSE:9334
|
Malaysia | RM79.89 Million |
|
G11 Resources Ltd
AU:G11
|
Australia | AU$161.95K |
|
Denge Yatirim Holding AS
IS:DENGE
|
Turkey | TL576.37 Million |
|
EP Manufacturing Bhd
KLSE:7773
|
Malaysia | RM285.93 Million |
|
Biohit Oyj B
HE:BIOBV
|
Finland | €4.90 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Eastwood Bio-Medical Canada Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 7.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eastwood Bio-Medical Canada Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eastwood Bio-Medical Canada Inc (2013–2024)
The table below shows the annual total liabilities of Eastwood Bio-Medical Canada Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-10-31 | CA$1.57 Million | +18.12% |
| 2023-10-31 | CA$1.33 Million | +51.35% |
| 2022-10-31 | CA$878.73K | +5.18% |
| 2021-10-31 | CA$835.44K | +76.21% |
| 2020-10-31 | CA$474.10K | +41.22% |
| 2019-10-31 | CA$335.73K | -7.11% |
| 2018-10-31 | CA$361.41K | +548.22% |
| 2017-10-31 | CA$55.76K | +56.77% |
| 2016-10-31 | CA$35.56K | -63.74% |
| 2015-10-31 | CA$98.08K | +9.98% |
| 2014-10-31 | CA$89.19K | -97.72% |
| 2013-10-31 | CA$3.92 Million | -- |
About Eastwood Bio-Medical Canada Inc
Eastwood Bio-Medical Canada Inc. markets and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia. The company distributes Eleotin, which provides natural remedies for metabolic disorders, such as blood glucose disorders, hypertension, and obesity. Its licensed products include Eleotin A 700 for the treatment for spleen deficiency, lack of appetite, a… Read more